Monday, March 09, 2009 11:19:53 AM
As Dew (who I suspect would not agree with the above statement) did indicate, 'Ampakines' played zero role in whatever calculations went into this plan--which is all about shoring up products-on-the-market in the face of patent expiration.
The only positive fact is that to the degree to which SP may be looking at an Ampakine licensing, such a deal is so small that it probably would not be affected much by a merger. Had SP been thinking about acquiring Cortex, which I don't think is the case, that would be derailed, but not tiny licensing deals. Reviewing all of the neuroscience programs to decide what to cull or keep is probably a year away.
Merck has not been an ADHD player, so this can't be seen as a plus for Org-26576, though if data is positive, it could still be brought ahead. Darryle Schoepp, who I know slightly, is Merck's head of neuroscience, and is a mGluR specialist. He is acquainted with Ampakines, since he was previously at Lilly, and he is at least obliquely acquainted with Cortex, since he has been a NI subscriber for many years.
Bottom line for Cortex: Cortex/Ampakines constitute such a small issue that, if either Merck or Schering (far more likely the latter) had a licensing interest in ADHD, this would not necessarily interfere with it much, though for Cortex, even a few weeks of delay is now relevant. Neither company would likely have been a RD/sleep apnea partnering candidate, so this is probably a nonfactor therein.
But this merger will keep larger companies running around like barflies at last call trying to figure out who to hook up with before closing time. A real waste of effort, and reflecting a profound dearth of creativity.
NeuroInvestment
Recent RSPI News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2024 12:45:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 12:30:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 08:01:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 01:03:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 01:30:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:45:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 01:45:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/17/2023 09:06:03 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 09:05:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 01:00:21 PM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM